Read these Instructions for Use which come with ONZETRA® Xsail® before you start using it and each time you get a refill. Follow these instructions each time you use ONZETRA Xsail.
These Instructions for Use have been approved by the U.S. Food and Drug Administration.
ONZETRA and Xsail are registered trademarks of Currax™ Pharmaceuticals LLC in the United States and other countries. The other brands listed are trademarks of their respective owners and are not trademarks of Currax™ Pharmaceuticals LLC. The makers of these brands are not affiliated with and do not endorse Currax™ Pharmaceuticals LLC or its products.
U.S. Patent Nos, 6,715,485; 7,975,690; 8,047,202; 8,327,844; 8,550,073; 8,555,877; 8,590,530; 8,875,704; 8,899,229; 8,978,647; 9,108,015; 9,119,932
Currax™ Pharmaceuticals LLC
Morristown, NJ 07960
Issued December 2019
© 2019 Currax™ Pharmaceuticals LLC. All rights reserved
(sumatriptan nasal powder)
11 mg per nosepiece
For Intranasal Use Only
PLEASE READ INSTRUCTIONS FOR USE.
FOR USE WITH XSAIL®
INTRANASAL DEVICE ONLY
intranasal medicationdelivery system
|ONZETRA XSAIL sumatriptan succinate capsule|
|Labeler — Currax Pharmaceuticals LLC (117055730)|
|PTI Royston LLC||601006997||MANUFACTURE (42847-311)|
|UPM Pharmaceuticals, Inc||081301372||MANUFACTURE (42847-311)|
|NATCO Pharma Limited, Chemical Division||862497174||API MANUFACTURE (42847-311)|
|Patheon, Inc||240769596||ANALYSIS (42847-311)|
Revised: 07/2021 Currax Pharmaceuticals LLC
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.